GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)
详细信息 查看全文
- 作者：Andrés Poveda (1)
Xavier García del Muro (2)
Jose Antonio López-Guerrero (3)
Virginia Martínez (4)
Ignacio Romero (1)
Claudia Valverde (5)
Ricardo Cubedo (6)
Javier Martín-Broto (7) - 关键词：GIST ; Imatinib ; Sunitinib ; CD117 ; c ; kit ; PDFGRA
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2014
- 出版时间：November 2014
- 年：2014
- 卷：74
- 期：5
- 页码：883-898
- 全文大小：384 KB
- 参考文献：1. Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch Int J Pathol. 438(1):1-2. PubMed PMID: 11213830
2. Lau S, Tam KF, Kam CK, Lui CY, Siu CW, Lam HS, et al (2004) Imaging of gastrointestinal stromal tumour (GIST). Clin Radiol.59(6):487-98. PubMed PMID: 15145718
3. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Comp Cancer 8 (Suppl 2):S1-41; quiz S2-4. PubMed PMID: 20457867
4. Lee CM, Chen HC, Leung TK, Chen YY (2004) Gastrointestinal stromal tumor: computed tomographic features. World J Gastroenterol 15;10(16):2417-418. PubMed PMID: 15285033
5. Casali PG, Blay JY, Experts ECECPo (2010) Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v98–v102 CrossRef
6. Bensimhon D, Soyer P, Boudiaf M, Fargeaudou Y, Nemeth J, Pocard M et al (2009) Imaging of gastrointestinal stromal tumors. J Radiol 90(4):469-80. PubMed PMID: 19503028
7. Tio TL, Tytgat GN, den Hartog Jager FC (1990) Endoscopic ultrasonography for the evaluation of smooth muscle tumors in the upper gastrointestinal tract: an experience with 42 cases. Gastrointest Endosc 36(4):342-50 CrossRef
8. Lamba G, Gupta R, Lee B, Ambrale S, Liu D (2012) Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol 1(1):14. PubMed PMID: 23210689. Pubmed Central PMCID: 3514103
9. Miettinen M, Majidi M, Lasota J (2002) Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 38(Suppl 5):S39–S51 CrossRef
10. Miettinen M, Lasota J, Sobin LH (2005) Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 29(10):1373-381. PubMed PMID: 16160481. Epub 2005/09/15. eng
11. Rubin BP (2006) Gastrointestinal stromal tumours: an update. Histopathology. 48(1):83-6. PubMed PMID: 16359540
12. Gasparotto D, Rossi S, Bearzi I, Doglioni C, Marzotto A, Hornick JL et al (2008) Multiple primary sporadic gastrointestinal stromal tumors in the adult: an underestimated entity. Clin Cancer Res 15;14(18):5715-721. PubMed PMID: 18779314
13. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130(10):1466-478
14. Lin SC, Huang MJ, Zeng CY, Wang TI, Liu ZL, Shiay RK (2003) Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors. World J Gastroenterol 9(12):2809-812
15. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33(5):459-65. PubMed PMID: 12094370. Epub 2002/07/03. eng
16. Rubin BP, Blanke CD, Demetri GD, Dematteo RP, Fletcher CD, Goldblum JR et al (2010) Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med 134(2):165-70. PubMed PMID: 20121601
17. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer 15;103(4):821-29. PubMed PMID: 15648083
18. Liegl B, Hornick JL, Corless CL, Fletcher CD (2009) Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 33(3):437-46. PubMed PMID: 19011564
19. Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer A et al (2004) Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 202(4):430-38 CrossRef
20. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC et al (2004) KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28(7):889-94 Ignacio Romero (1)
Claudia Valverde (5)
Ricardo Cubedo (6)
Javier Martín-Broto (7)
1. Instituto Valenciano de Oncología, Calle del Profesor Beltrán Bàguena, 8, 46009, Valencia, Spain
2. Institut Català d’Oncologia, Avinguda de la Granvia de l’Hospitalet, 199-203, 08907, L’Hospitalet de Llobregat, Barcelona, Spain
3. Fundación Instituto Valenciano de Oncología, C/Prof Baguena, 19, 46009, Valencia, Spain
4. Hospital La Paz, Paseo de la Castellana, 261, 28046, Madrid, Spain
5. Hospital Vall d’Hebrón, Passeig de la Vall d’Hebrón 119-129, 08035, Barcelona, Spain
6. Hospital Puerta de Hierro, Calle Manuel de Falla, 1, 28222, Majadahonda, Madrid, Spain
7. Hospital Virgen del Rocío, Avda. Manuel Siurot s/n, 41013, Sevilla, Spain - ISSN：1432-0843
文摘
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal soft tissue sarcoma of the gastrointestinal tract. Correct diagnosis with thorough use of pathologic and molecular tools of GIST mutations has been of the foremost importance. GIST are usually (95?%) KIT positive and harbor frequent KIT or platelet-derived growth factor receptor α-activating mutations. This deep molecular understanding has allowed the correct classification into risk groups with implications regarding prognosis, essential use in the development of targeted therapies and even response prediction to this drugs. Treatment has been evolving and an update to include lessons learned from recent trials in advanced disease as well as controversies in the adjuvant setting that are changing daily practice, is reviewed here. An effort from the Spanish Group for Sarcoma Research with investigators from the group has been undertaken to launch this third version of the GIST guidelines and provide a practical means for the different disciplines that treat this complex disease.